Loading [MathJax]/jax/output/SVG/jax.js
Review Topical Sections

Halophilic microorganism resources and their applications in industrial and environmental biotechnology

  • Received: 16 December 2015 Accepted: 28 February 2016 Published: 01 March 2016
  • Hypersaline environments are extreme habitats on the planet and have a diverse microbial population formed by halophilic microorganisms. They are considered to be actual or potential sources for discovery bioactive compounds, compatible solutes including novel and/or extraordinarily enzymes. To date, a number of bioactive compounds for the use in various fields of biotechnology which show assorted biological activities ranging from antioxidant, sunscreen and antibiotic actions have been reported. In addition, some halophilic microorganisms are capable of producing massive amounts of compatible solutes that are useful as stabilizers for biomolecules or stress-protective agents. The present review will impart knowledge and discuss on (i) potential biotechnological applications of bioactive compounds, compatible solutes and some novel hydrolytic enzymes; (ii) recent efforts on discovery and utilization of halophiles for biotechnological interest; (iii) future perspective of aforementioned points.

    Citation: Rungaroon Waditee-Sirisattha, Hakuto Kageyama, Teruhiro Takabe. Halophilic microorganism resources and their applications in industrial and environmental biotechnology[J]. AIMS Microbiology, 2016, 2(1): 42-54. doi: 10.3934/microbiol.2016.1.42

    Related Papers:

    [1] Sandesh Athni Hiremath, Christina Surulescu, Somayeh Jamali, Samantha Ames, Joachim W. Deitmer, Holger M. Becker . Modeling of pH regulation in tumor cells: Direct interaction between proton-coupled lactate transporters and cancer-associated carbonicanhydrase. Mathematical Biosciences and Engineering, 2019, 16(1): 320-337. doi: 10.3934/mbe.2019016
    [2] Allen L. Nazareno, Raymond Paul L. Eclarin, Eduardo R. Mendoza, Angelyn R. Lao . Linear conjugacy of chemical kinetic systems. Mathematical Biosciences and Engineering, 2019, 16(6): 8322-8355. doi: 10.3934/mbe.2019421
    [3] OPhir Nave, Shlomo Hareli, Miriam Elbaz, Itzhak Hayim Iluz, Svetlana Bunimovich-Mendrazitsky . BCG and IL − 2 model for bladder cancer treatment with fast and slow dynamics based on SPVF method—stability analysis. Mathematical Biosciences and Engineering, 2019, 16(5): 5346-5379. doi: 10.3934/mbe.2019267
    [4] Amer Hassan Albargi, Miled El Hajji . Mathematical analysis of a two-tiered microbial food-web model for the anaerobic digestion process. Mathematical Biosciences and Engineering, 2023, 20(4): 6591-6611. doi: 10.3934/mbe.2023283
    [5] Blessing O. Emerenini, Stefanie Sonner, Hermann J. Eberl . Mathematical analysis of a quorum sensing induced biofilm dispersal model and numerical simulation of hollowing effects. Mathematical Biosciences and Engineering, 2017, 14(3): 625-653. doi: 10.3934/mbe.2017036
    [6] Urszula Foryś, Jan Poleszczuk . A delay-differential equation model of HIV related cancer--immune system dynamics. Mathematical Biosciences and Engineering, 2011, 8(2): 627-641. doi: 10.3934/mbe.2011.8.627
    [7] Swadesh Pal, Malay Banerjee, Vitaly Volpert . Spatio-temporal Bazykin’s model with space-time nonlocality. Mathematical Biosciences and Engineering, 2020, 17(5): 4801-4824. doi: 10.3934/mbe.2020262
    [8] Awatif Jahman Alqarni, Azmin Sham Rambely, Sana Abdulkream Alharbi, Ishak Hashim . Dynamic behavior and stabilization of brain cell reconstitution after stroke under the proliferation and differentiation processes for stem cells. Mathematical Biosciences and Engineering, 2021, 18(5): 6288-6304. doi: 10.3934/mbe.2021314
    [9] Boumediene Benyahia, Tewfik Sari . Effect of a new variable integration on steady states of a two-step Anaerobic Digestion Model. Mathematical Biosciences and Engineering, 2020, 17(5): 5504-5533. doi: 10.3934/mbe.2020296
    [10] Pei Yu, Xiangyu Wang . Analysis on recurrence behavior in oscillating networks of biologically relevant organic reactions. Mathematical Biosciences and Engineering, 2019, 16(5): 5263-5286. doi: 10.3934/mbe.2019263
  • Hypersaline environments are extreme habitats on the planet and have a diverse microbial population formed by halophilic microorganisms. They are considered to be actual or potential sources for discovery bioactive compounds, compatible solutes including novel and/or extraordinarily enzymes. To date, a number of bioactive compounds for the use in various fields of biotechnology which show assorted biological activities ranging from antioxidant, sunscreen and antibiotic actions have been reported. In addition, some halophilic microorganisms are capable of producing massive amounts of compatible solutes that are useful as stabilizers for biomolecules or stress-protective agents. The present review will impart knowledge and discuss on (i) potential biotechnological applications of bioactive compounds, compatible solutes and some novel hydrolytic enzymes; (ii) recent efforts on discovery and utilization of halophiles for biotechnological interest; (iii) future perspective of aforementioned points.


    1. Introduction

    The brain is an organ with high energy needs. While it represents only 2% of the body weight it grabs at least 20% of its total energy needs [9]. The consumed energy can come from many forms such as glutamate, glucose, oxygen and also lactate [3]. Energy is necessary to support neural activity. Gliomas are the most frequent primary brain tumors (more than 50% of brain cancer cases according to the ICM institute). Like other cancers, they lead to alterations of cells' energy management. In particular, lactate creation, consumption, import and export of a glioma cell seem to play a key role in the cancer development [5]-[11]. Today, neuroimaging techniques allow an indirect and noninvasive measure of cerebral activity. It also enables measurement of various metabolic concentrations such as lactate and measurement of important biological parameters such as the relative cerebral blood volume (allowing relative cerebral blood flow calculations). But because energy management in healthy and tumoral cells and glioma growth can be difficult to observe and explain experimentally, we propose to use mathematical modeling to help to describe and understand cells energy changes.

    To the best of our knowledge, only a few mathematical models have been proposed to study lactate fluxes in the brain and the interconnections with energy, see [3] for example. We aim herein at analyzing a model first described in [2].

    Our paper is organized as follows. We first present the mathematical model proposed to describe the mechanisms of interest. We then investigate its well-posedness and derive bounds on the solutions. Indeed, such an analysis is necessary to justify how a mathematical model is well-adapted to a biological problem. We also analyze the limit model and study its steady state. Bounds on the solutions are important as they are related with the viability domain of the cell. Furthermore, as mentioned in [8], a therapeutic perspective is to have the steady state outside the viability domain where cell necrosis occurs. Additionnally, we present numerical simulations with different values of the small parameter $\varepsilon$ and compare them with experimental data. We finally discuss our results.


    2. Mathematical modeling

    The present model is reduced in order to follow in a simpler way lacate kinetics between a cell and the capillary network in its neighborhood. It is built in vivo which means that we have to consider loss and input terms for both intracellular and capillary lactate concentrations. We denote by $u_{\varepsilon}$ the intracellular lactate concentration and $v_{\varepsilon}$ the capillary lactate concentration where $\varepsilon$ stands for the volume separating the compartments. They are given in mM. One of the main parameters in the model is $\varepsilon$. Indeed to manage the blood flow, vessels dilate and modify their volume. We cannot model this phenomenon in a simple mathematical way. It is thus important to know how variations of their volume correlated with variations of $\varepsilon$ impact the whole dynamics.

    First, there is a lactate cotransport through the brain blood. It is taken into account by a simplified version of an equation for carrier-mediated symport. This nonlinear term depends on the maximum transport rate between the blood and the cell $T>0$ and the modified Michaelis-Menten positive constant for both intracellular and capillary lactate concentrations ($k$ and $k'$ respectively).

    Then a cell can equally produce and consume lactate, but also export surplus lactate to neighboring cells. We denote by $J$ the balance sheet of the whole phenomenon. The function $J$ is a nonnegative function depending on $t$ and $u_{\varepsilon}$ seen as a regulatory term. It is assumed to be bounded by a constant $B_J$ and Lipschitz continuous.

    Next there is a blood flow contribution to capillary lactate depending on both arterial and venous lactates. We denote by $L>0$ the arterial lactate concentration. We also define the blood flow $F$. The function $F$ is a positive bounded continuous function ($F_1 <F <F_2$) seen as a forcing term.

    Finally, we have the following ODE's, for $t \in \mathbb{R}^+$:

    $ uε(t)=J(t,uε(t))T(uε(t)k+uε(t)vε(t)k+vε(t)), $ (2.1)
    $ εvε(t)=F(t)(Lvε(t))+T(uε(t)k+uε(t)vε(t)k+vε(t)). $ (2.2)

    The initial condition is given by :

    $(u_{\varepsilon}(0);v_{\varepsilon}(0)) = (\bar{u}_0;\bar{v}_0) \in \mathbb{R}^+\times \mathbb{R}^+.$

    The model is biologically described in [2], to which we refer the interested readers for a better understanding of this process.

    Figure 1. Schematic representation of lactate exchanges in a local brain part. There is a cotransport through the brain-blood barrier, a blood flow, cell creation and consumption and interactions between a cell and its neighborhood. Interactions are described in the main text.

    3. The case $\varepsilon>0$

    Well-posedness. Recall that an ODE system $x'(t) = f(t, x(t))$ on $\mathbb{R}^n$, $x = [x_1, \cdots, x_n]$, $f = [f_1, \cdots, f_n]$, is called quasipositive if the condition :

    $x \geqslant 0, x_k = 0 \Rightarrow f_k(t, x)\geqslant 0$

    is verified for all $k = 1, \cdots, n$. System (2.1)-(2.2) obviously is quasipositive. Hence solutions with nonnegative initial data $(\bar{u}_0;\bar{v}_0)$ remain in $(\mathbb{R}^{+})^{2}$ for all positive times.

    Since we have for nonnegative $u_1$ and $u_2$ :

    $|{\frac{u_1}{k+u_1}-\frac{u_2}{k+u_2}}| = \frac{k|{u_2-u_1}|}{(k+u_1)(k+u_2)} \leqslant \frac{|{u_2-u_1}|}{k}, $

    then we can rewrite (2.1)-(2.2), setting

    $X(t):=(uε(t);vε(t)),$

    to have $\forall t \in \mathbb{R}^+$ :

    $X'(t) = H(t, X(t)), ~~~~~~~~~ X(0) = X_0, $

    where $H$ is globally Lipschitz continuous with respect to the second variable. We finally conclude, thanks to the Cauchy-Lipschitz theorem, that we have existence and uniqueness of the solution to the system $\forall t \in \mathbb{R}^+$.

    Bounds on the solution. By means of (2.2), we have $\forall t \in \mathbb{R}^+$,

    $v_{\varepsilon}'(t) \leqslant -\frac{F_1 v_{\varepsilon}(t)}{\varepsilon}+\frac{F_2L}{\varepsilon}+\frac{T}{\varepsilon}, $

    which implies, using Gronwall's lemma, that

    $v_{\varepsilon}(t) \leqslant \exp (\frac{-F_1 t}{\varepsilon})\bar{v}_0+\int_0^t \exp (\frac{-F_1 (t-s)}{\varepsilon})\frac{T+F_2L}{\varepsilon}ds, $

    or equivalently,

    $v_{\varepsilon}(t) \leqslant \exp (\frac{-F_1 t}{\varepsilon})\bar{v}_0+\frac{T+F_2L}{F_1}(1- \exp (\frac{-F_1 t}{\varepsilon})).$

    One can see, using the above formula, that we have $\forall t \in \mathbb{R}^+$,

    $v_{\varepsilon}(t) \leqslant \max(\bar{v}_0, \frac{T+F_2L}{F_1}): = B_v. \label{Bv} $

    Theorem 3.1. We can exhibit a sufficient, but not necessary, condition to ensure a bound on $u_{\varepsilon}$. When it exists, let $B_J \in \mathbb{R}$ be such that :

    $\forall (t, x) \in \mathbb{R}^2, \ J(t, x) \leqslant B_J$

    and :

    $BJ<T(1Bvk+Bv)BJ(k+Bv)<Tk.(C2.1)$

    In that case, we have, setting $z = \frac{B_v}{k'+B_v}+\frac{B_J}{T}$ and $\forall t \in \mathbb{R}^+$ :

    $ uε(t)max(kz1z,ˉu0):=Bu. $ (3.1)

    Remark 1. Condition $(C_{2.1})$ is related to the equation $f(x) = 0$ with $f(x) = B_J-\frac{Tx}{k+x}+\frac{TB_v}{k'+B_v}$ for which a positive solution exists if and only if $B_J <T(1-\frac{B_v}{k'+B_v})$, i.e. $(C_{2.1})$ holds. From a biological point of view, this condition means that at each time the lactate uptake by a cell (from itself or its neighborhood) cannot be larger than the lactate it can purge through the blood. Otherwise, the cell lactate concentration increase may not be limited.

    Proof. Equation (2.1) gives $\forall t \in \mathbb{R}^+$ :

    $u_{\varepsilon}'(t) \leqslant B_J+ T\frac{B_v}{B_v+k'}-T\frac{u_{\varepsilon}(t) }{k+u_{\varepsilon}(t) }.$

    We set $z = \frac{B_v}{k'+B_v}+\frac{B_J}{T}$ and have, thanks to (C$_{2.1}$) :

    $1-z = \frac{(k'+B_v)T}{(k'+B_v)T}-\frac{B_v(T+B_J)+k'B_J}{(k'+B_v)T} = \frac{k'T-B_J(k'+B_v)}{(k'+B_v)T} > 0.$

    Let $t \in \mathbb{R}^+$ be such that:

    $u_{\varepsilon}(t) > \frac{kz}{1-z}.$

    Then,

    $u_{\varepsilon}(t)(1-\frac{B_v}{k'+B_v}-\frac{B_J}{T}) > k(\frac{B_v}{k'+B_v}+\frac{B_J}{T}), $

    which yields

    $B_J+ T\frac{B_v}{B_v+k'}-T\frac{u_{\varepsilon}(t)}{k+u_{\varepsilon}(t)} < 0, $

    hence

    $ u_{\varepsilon}'(t) < 0. $

    We finally deduce that

    $uε(t)max(kz1z,ˉu0).$

    Remark 2. This condition on an upper bound on $J$ is sufficient but not necessary. We can actually also consider functions $J$ which do not satisfy (C$_{2.1}$) but for which, when $u_{\varepsilon}$ is large, we can exhibit a better upper bound satisfying (C$_{2.1}$). It is thus sufficient to write that $u_{\varepsilon}$ is bounded from above with a mild (C$_{2.1}$) condition. For example, we can take $J = J_{test}$ such that, $\forall (x, s) \in \mathbb{R}^+\times\mathbb{R}^+$ :

    $J_{test}(s, x) = \underbrace{G_J}_{\text{creation}}-\underbrace{L_J}_{\text{ consumption}}+\underbrace{\frac{C_J}{\varepsilon_J+x}}_{\text{import}}, $

    for positive constants $G_J$, $L_J$, $C_j$ and $\varepsilon_J$ such that $G_J>L_J$ and $G_J <L_J+\frac{Tk'}{k'+B_v}$. The second condition means that the lactate creation of the cell is smaller than its consumption and purge through the blood, so that the cell is able to manage lactate excess. Then, for $x \geqslant \frac{C_j}{\frac{Tk'}{k'+B_v}-G_J+L_J} = N_{test}$, $J_{test}$ is bounded by $\frac{Tk'}{k'+B_v}$ and satisfies (C$_{2.1}$). We conclude that, setting $z = \frac{B_v}{k'+B_v}+\frac{B_J}{T}$, then $u(t) \leqslant \max(N_{test}, \frac{kz}{1-z}, \bar{u}_0)$, $\forall t \in \mathbb{R}^+$. Even though we cannot assert that such a function $J$ is biologically relevant, it is improbable to find relevant functions $J$ leading to a fatal lactate increase in the cell. In fact, it is logical to expect functions decreasing in $x$, since, when a cell has more substrate than necessary for it to live on its own, it does not have to import or create more.

    We have already proved that $u_{\varepsilon}$ and $v_{\varepsilon}$ are nonnegative functions. We can exhibit lower bounds by using the same method. Indeed, (2.2) gives, $\forall t \in \mathbb{R}^+$ :

    $v_{\varepsilon}'(t) \geqslant -\frac{F_2 v_{\varepsilon}(t)}{\varepsilon}+\frac{F_1L}{\varepsilon}-\frac{T}{\varepsilon}\frac{B_v}{k'+B_v}.$

    Then, if $\frac{F_1L-T\frac{B_v}{k'+B_v}}{F_2} \geqslant 0 $ and for $t \in \mathbb{R}^+$ such that

    $v_{\varepsilon}(t) \leqslant \frac{F_1L-T\frac{B_v}{k'+B_v}}{F_2}, $

    we have $v_{\varepsilon}(t)'\geqslant 0$, so that, $\forall t \in \mathbb{R}^+$ :

    $vε(t)min(ˉv0,F1LTBvk+BvF2).$

    If $\frac{F_1L-T\frac{B_v}{k'+B_v}}{F_2} \leqslant 0 $, we cannot find a positive lower bound on $v_{\varepsilon}$ and we keep $v_{\varepsilon} \geqslant 0$. Finally :

    $ vε(t)min(ˉv0,max(F1LTBvk+BvF2,0)):=Mv. $ (3.2)

    Similarly, $\forall t \in \mathbb{R}^+$ :

    $uε(t)T(Mvk+Mvuεk+uε).$

    Then $u_{\varepsilon}(t)\leqslant M_v\frac{k}{k'}$ leads to $u'(t)\geqslant 0$. This shows that

    $ uε(t)min(ˉu0,Mvkk):=Mu. $ (3.3)

    Remark 3. The upper bound $B_v$ on $v_{\varepsilon}$ can be derived even when the initial data $\bar{v}_0$ and $\bar{u}_0$ depend on $\varepsilon$ and are bounded with respect to this parameter. To do so, we use the same method, adapting the final step so that

    $v_{\varepsilon}(t) \leqslant \max( \underset{\varepsilon>0}{\sup{\bar{v}_0}}, \frac{T+F_2L}{F_1}) .$

    The lower bounds $M_v$ and $M_u$ can be obtained in the same way for initial data depending on $\varepsilon$.

    Stability of the equilibrium. For constant $J$ and $F$, an equilibrium for (2.1)-(2.2) has been found in [4] :

    $ ul:=k(JT+vlk+vl)1(JT+vlk+vl), $ (3.4)
    $ vl:=L+JF. $ (3.5)

    It has also been proven that this unique stationary point is a node, hence a locally stable equilibrium. However, this equilibrium does not always exist. For existence, the parameters need to satisfy :

    $ JT+LF+JF(k+L)+J<1J2+JF(L+k)TFk<0. $ (3.6)

    Remark 4. We have already shown that $v_{\varepsilon}(t) \leqslant L+\frac{T}{F} = B_v$, $\forall t \in \mathbb{R}^+$. We verify that the equilibrium $v_l$ is such that $v_l\leqslant B_v$, which requires $J\leqslant T$. In fact, under $(2.7)$, $J > T$ implies:

    $J^2+JF(L+k')-TFk'> T^2+TF(L+k')-TFk' = T(T+FL) > 0.$

    Therefore, the contraposition leads to:

    $J^2+JF(L+k')-TFk'\leqslant 0 \text{ implies } J \leqslant T.$

    We fix all the parameters but $J$. Then, we wish to rewrite this condition by giving it in terms of $J$. In this way, we have :

    $\Delta_J = F^2(L+k')^2+4TFk'>0$

    and there is an equilibrium only when $J \in]J_b, J_h[$, where :

    $Jb:=12(F(L+k)ΔJ),Jh:=12(F(L+k)+ΔJ).$

    Knowing that $J$ is nonnegative, there are only two possible cases :

    1. $0 <J <J_h$ with one steady-state which is a node,

    2. $J>J_h$ with no steady-state.

    A therapeutic perspective is to have the steady state outside the viability domain [8]. Therefore playing on cell lactate intake could be worth exploring: a large $J$ involves an unbounded cell lactate concentration which leads to an exit of the cell viability domain and, finally, the glioma cell death.


    4. The case $\varepsilon=0$

    We now study the limit system for $\varepsilon = 0 $, $F(t): = F$, $J(t, x): = J$ constant, given $\forall~t \in \mathbb{R}^+$ by :

    $ u0(t)=JT(u0(t)k+u0(t)v0(t)k+v0(t)), $ (4.1)
    $ 0=F(Lv0(t))+T(u0(t)k+u0(t)v0(t)k+v0(t)), $ (4.2)

    together with the initial condition :

    $u_0(0) = \bar{u}_0 \in \mathbb{R}^+.$

    We first give some preliminary results and then establish bounds on the solutions and study the well-posedness of the system. We finally compare the original system (with $\varepsilon>0$) with this limit system (with $\varepsilon = 0$).

    Preliminaries. The function $v_{0}$ given by (4.2) is defined as long as $v_{0}(t)$ belongs to $I =]-\infty, -k'[~\cup~]-k', +\infty[: = I_1~\cup~I_2$ and is continuous. Taking $v_{0}(0) = \tilde{v}_0 \in I_2$, then $v_{0}(t) \in I_2$ $\forall~t \in \mathbb{R}^+$. It is biologically relevant to take $v_0(0) = \tilde{v}_0 $ as the positive root of (4.2) for $u_0(0) = \bar{u}_0$.

    We define the function $\varphi_c$, for any constant $c>0$, by :

    ${\varphi _c}\left\{ ]c,+[],T[sTsc+s. \right.$

    It is easy to see that $\varphi_c$ is a monotone increasing function with $\varphi_c(0) = 0$. We also define an inverse function of $\varphi_c$ :

    $\varphi _c^{ - 1}\left\{ [0,T[[0,+[zczTz. \right.$

    Furthermore, we introduce the function $\psi_c$ defined by :

    ${{\psi }_{c}}\left\{ ]c,+[R           sFs+φc(s), \right.$

    where $\psi_c$ is a bijection from $]-c, +\infty[$ onto $\mathbb{R}$. It can also be a bijection from $\mathbb{R}^+$ onto itself. Its derivative reads :

    $\psi_c'(s) = F+\frac{Tc}{(c+s)^2}.$

    Employing (4.2), we have :

    $\psi_{k'}(v_0(t)) = FL+\varphi_k(u_0(t)).$

    We rewrite (4.1)-(4.2) as :

    $ v0(t)=ψ1k(FL+φk(u0(t))):=Ψ(u0(t)), $ (4.3)
    $ u0(t)=JT(u0(t)k+u0(t)Ψ(u0(t))k+Ψ(u0(t))):=G(t,u0(t)), $ (4.4)

    and set, for $y\in[0, +\infty[$ :

    $Ψ1(y)=φ1k(ψk(y)FL).$

    A priori bounds on the solutions. Thanks to (4.4), we have :

    $G(t, 0) = J+\frac{T\psi_{k'}^{-1}(FL)}{k'+\psi_{k'}^{-1}(FL)}\geqslant J, $

    and the system is quasipositive : for an initial condition $\bar{u}_0\geqslant 0$, there holds $u_{0}(t)\geqslant 0$, $\forall t \in \mathbb{R}^+$. A fortiori, we have $v_{0}(t) = \Psi(u_{0}(t)) \geqslant 0$.

    Using (4.2), we find an upper bound on $v_0$, $\forall t \in \mathbb{R}^+$ :

    $ v0(t)L+TF:=Bv,0. $ (4.5)

    We can also obtain an upper bound on $u_0$ using Theorem 2.1. When it exists, we call it $B_{u, 0}$.

    We now rewrite (4.2) as :

    $v_{0}(t)^2+v_{0}(t)(k'-L+\frac{T}{F}-z)-k'(L+z) = 0, $

    where $z = \frac{Tu_{0}(t)}{(k+u_{0}(t))F}\leqslant \frac{T}{F}$.

    Noting that $v_{0}$ is positive, $\forall t \in \mathbb{R}^+$, we have :

    $ v0(t)=12(z+LTFk+(TF+kLz)2+4k(L+z)). $ (4.6)

    Well-posedness. Equation (4.4) gives :

    $u0(t)=JT(u0(t)k+u0(t)Ψ(u0(t))k+Ψ(u0(t))):=G(t,u0(t)).$

    Lemma 1. The function $\Psi$ is Lipschitz continuous in $u_0$, i.e. there exists $K_L>0$ such that for all $u_1, u_2 \in [0, +\infty], $

    $|{\Psi(u_1)-\Psi(u_2)}| \leqslant K_L |{u_1-u_2}|.$

    Proof. Let $u \in \mathbb{R}^+$. We know that :

    $Ψ(u)=1(Ψ1)(Ψ(u))$

    and :

    $|(Ψ1)(Ψ(u))|=|(φ1k)(ψk(Ψ(u))FL)ψk(Ψ(u)))|=|Tk(Tψk(Ψ(u))+FL)2(F+Tk(k+Ψ(u))2)|=|Tk(Tk+F(k+Ψ(u))2)(T+φk(u))2(k+Ψ(u))2|.$

    It follows from the above that $\Psi(u) = v$, with :

    $0=F(Lv)+T(uk+uvk+v)vFL+T=Bv,0,v0.$

    Therefore, $\Psi(u) = v \in [0, B_{v, 0}]$ and :

    $|Ψ(u)|=1|(Ψ1)(Ψ(u))|=|(T+φk(u))2(k+Ψ(u))2Tk(Tk+F(k+Ψ(u))2)|(T+Tuk+u)2(k+Ψ(u))24T2(k+Bv,0)2:=KL.$

    Consequently, $G(t, u_{0})$ is Lipschitz continuous in $u_{0}$. Therefore, thanks to the Cauchy-Lipschitz theorem, we have the existence and uniqueness of the solution to (4.4), $\forall t \in \mathbb{R}^+$. Finally we have existence and uniqueness for $v_0$, recalling that $\Psi$ is a bijection.

    Stability of the equilibrium. As proved in [3], (4.1)-(4.2) can have at most one equilibrium given under the above parameters condition. The Jacobian of the system at this point gives the eigenvalue :

    $\lambda: = -T \frac{k}{(k+u_l)^2} <0.$

    Therefore, $u_l$ is locally stable. Moreover, $\forall t \in \mathbb{R}^+$, $v(t) = \Psi(u(t))$, where $\Psi$ is a bijective function. Setting $z_l = \frac{J}{T}+\frac{v_l}{k'+v_l}$, we have :

    $Tulk+ul=Tkzl1zl1zlk=Tzl=TJT+Tvlk+vl=F(JF+LL)+Tvlk+vl=F(vlL)+Tvlk+vl.$

    Thus :

    $Fv_l+T\frac{v_l}{k'+v_l} = FL+T\frac{u_l}{k+u_l} \Leftrightarrow v_l = \Psi(u_l), $

    and the stationnary point $v_l$ is locally stable.

    Comparison between the original and the limit systems. We wish to bound the difference between $(u_{\varepsilon};v_{\varepsilon})$ solution to (2.1)-(2.2) with $F(t): = F$ and $J(t, x): = J$ and $(u_{0};v_{0})$ solution to (4.1)-(4.2), $\forall t \in \mathbb{R}^+$. To do so, we choose the same initial condition for $u_{\varepsilon}$ and $u_0$ :

    $u_{\varepsilon}(0) = u_0(0) = \bar{u}_0.$

    We set $u = u_{\varepsilon}-u_{0}$ and $v = v_{\varepsilon}-v_0$. Using (2.1), (2.2), (4.1) and (4.2), we have, $\forall~t \in \mathbb{R}^+$ :

    $ u(t)=T(kv(t)(vε(t)+k)(v0(t)+k)ku(t)(uε(t)+k)(u0(t)+k)), $ (4.7)
    $ εv(t)=Fv(t)+T(ku(t)(uε(t)+k)(u0(t)+k)kv(t)(vε(t)+k)(v0(t)+k))εv0(t). $ (4.8)

    It follows from the above that, $\forall~t \in \mathbb{R}^+$ :

    $u0(t)=JT(u0(t)k+u0(t)v0(t)k+v0(t))[JT,J+T],v0(t)Bv,0,$

    Therefore, differentiating (4.2), we find :

    $Fv0(t)=T(ku0(t)(k+u0(t))2kv0(t)(k+v0(t))2)v0(t)(F+kT(k+v0(t))2)=Tku0(t)(k+u0(t))2,$

    hence $\forall~t \in \mathbb{R}^+$ :

    $|{v_{0}'(t)}| \leqslant \frac{kT(J+T)}{(F+\frac{k'T}{(k'+B_{v, 0})^2})}: = \gamma.$

    Next, multiplying $(4.7)$ by $u(t)$ and $(4.8)$ by $v(t)$ gives, $\forall~t \in \mathbb{R}^+$ :

    $ 12ddt(u2(t))Tk|u(t)||v(t)|, $ (4.9)
    $ ε12ddt(v2(t))+Fv2(t)Tk|u(t)||v(t)|+ε|v(t)|γ. $ (4.10)

    Noting that

    $Tk|u(t)||v(t)|+ε|v(t)|γ=(Tk|u(t)|2F)(F2|v(t)|)+(|v(t)|F2)(2Fεγ)F2v2(t)+4T2Fk2u2(t)+4γ2Fε2$

    and

    $Tk|u(t)||v(t)|=(Tk|u(t)|2F)(F2|v(t)|)F2v2(t)+2T2Fk2u2(t),$

    summing (4.9) and (4.10) thus yields, $\forall~t \in \mathbb{R}^+$ :

    $ddt(u2(t)+εv2(t))(8T2Fk2+4T2Fk2)(u2(t)+εv2(t))+8γ2Fε2.$

    Noting finally that :

    $u^2(0) = 0 \text{ and }u^2(0)+\varepsilon v^2(0) = \varepsilon (\bar{v}_0-\Psi(\bar{u}_0))^2, $

    Gronwall's lemma gives, $\forall~t \in \mathbb{R}^+$ :

    $u2(t)+εv2(t)exp(T2tF(8k2+4k2))(ε(ˉv0Ψ(ˉu0))2+k2(J+T)2(F+kT(k+L+TF)2)22ε2(2k2+1k2))k2(J+T)2(F+kT(k+L+TF)2)22ε2(2k2+1k2).$

    Remark 5. In the particular case $\bar{v}_0 = \Psi(\bar{u}_0)$, we have $\forall t \in [0, t_m]$ :

    $u2(t)+εv2(t)(exp(T2tmF(8k2+4k2))1)2γ2ε2T2(2k2+1k2)$

    which yields that, on the finite time interval $[0, t_m]$,

    $ |u(t)|Ctmε,|v(t)|Ctmε. $ (4.11)

    Remark 6. Setting $v_{0}(0) = \tilde{v}_1 \in I_1$ the negative root of (4.2) for $u_0(t) = \bar{u}_0$, we define a second solution to (4.1)-(4.2) for every $t \in \mathbb{R}^+$. We strongly think that we can study this degenerate system with similar mathematical tools, but this does not make sense from a biological point of view.


    5. Numerical simulations and comparison with experimental data

    In this section, we first present several numerical simulations with relevant values of our parameters. We also compare the numerical simulations with different values of $J$ and $\varepsilon$. We finally give and study experimental data. These simulations have been done with the Matlab software.

    Numerical illustration with nonconstant $J$ and $F$. We first consider the system given by (2.1)-(2.2). We expect that a cell manages its lactate concentration by means of its amount but not of the experiment's duration. Therefore we assume that it is biologically relevant to take a function $J$ that does not depend of $t$. Besides, we expect that a cell imports more lactate when its lactate concentration is low. In other words $J$ should be monotone decreasing in $x$. Under this hypothesis we choose :

    $J\left\{ R+R+   xGJLj+Cjx+εj, \right.$

    containing a creation term, a consumption term and an import term. This function $J$ is a bounded and Lipschitz continuous function which enjoys the mild (C$_{2.1}$) condition. We also define, as given in [1] :

    $F\left\{ \begin{array}{l}
    {\mathbb{R}^ + } \to {\mathbb{R}^ + }\\
    t \mapsto \left\{ \begin{array}{l}
    {F_0}(1 + {\alpha _f})\;\;\;{\rm{if}}\;\exists N \in\mathbb{N} /(N - 1){t_f} + {t_i}{\rm{ < }}t{\rm{ < }}N{t_f},\\
    \;\;\;\;\;\;\;\;\;\;\;\;{F_0}\;\;{\rm{if}}\;\;{\rm{not}}
    \end{array}
    \right. \end{array} \right.$

    The parameters for these two functions are given in Table 1.

    Table 1. Parameters for $F$ and $J$.
    ParameterValueUnit
    $F_0$0.012s$^{-1}$
    $\alpha_f$0.5 $1$
    $t_i$50 $s$
    $t_f$100 $s$
    $C_J$5.7*10$^{-5}$ $mM^2.s^{-1}$
    $\varepsilon_J$0.001 $mM$
    $G_J$0.002 $mM.s^{-1}$
    $L_J$0.001 $mM.s^{-1}$
     | Show Table
    DownLoad: CSV

    We also consider the parameters given in [2] and [8]. In that case, $(\bar{u}_0;\bar{v}_0) = (1.15;1)$ and the parameters values are given in Table 2.

    Table 2. Parameters values.
    ParameterValueUnit
    $T$0.01mM.s$^{-1}$
    $k$3.5mM
    $k'$3.5mM
    $L$0.3mM
    $\varepsilon$0.001s$^{-1}$
     | Show Table
    DownLoad: CSV

    The solutions $u_{\varepsilon}$ and $v_{\varepsilon}$ remain nonnegative, as shown in Figure 3. Here, we have an upper bound on $v_{\varepsilon}$ and J enjoys (C$_{2.1}$), so that $u_{\varepsilon}$ has an upper bound too. Thus, the intracellular and capillary lactate concentrations match with the mathematical analysis. At the beginning, there is a dip for the capillary lactate concentration. The fluctuations on $F$ are rapidly damped out as time grows.

    Figure 2. The functions $F$ and $J$; $F$ is a periodic function while $J$ is a monotone decreasing function of $u$.
    Figure 3. Intracellular and capillary lactate dynamics with nonconstant functions $J$ and $F$. On the left, the intracellular lactate trajectory is upper bounded. On the right, the capillary lactate trajectory is upper bounded too, but has an initial dip. At the bottom the orbit is typical of fast-slow systems.

    Numerical simulations with different values of $J$ and $\varepsilon$. We now assume that $J$ and $F$ are constant in order to compare (2.1)-(2.2) with (4.1)-(4.2). The parameters values are given in Table 3, following [2] and [8], and the simulations are displayed in Figure 4.

    Table 3. Parameters values.
    ParameterValueUnit
    $T$0.01mM.s$^{-1}$
    $k$3.5mM
    $k'$3.5mM
    $L$0.3mM
    $J$0.0057mM.s$^{-1}$
    $F$0.0272s$^{-1}$
    $\varepsilon$0.1s$^{-1}$
     | Show Table
    DownLoad: CSV
    Figure 4. Intracellular and capillary lactate dynamics with constant functions $J$ and $F$. The intracellular lactate trajectory (on the left) and the capillary lactate trajectory (on the right) are both upper bounded and reach the corresponding steady state. The trajectories for the original system (with $\varepsilon >0$) are also lower bounded. On the right top corner the capillary lactate of the original system has an initial dip, while it does not exist on the capillary lactate curve of the limit system (right bottom corner).

    Note that, in that case, we have shown the existence of an upper bound on $u$ and the presence of a locally stable steady state. The limit system has almost the same dynamics as the initial one. The notable difference is the presence of a hard initial dip for the dynamics of the capillary lactate with $\varepsilon>0$. This dip does not exist in the dynamics given by the limit system.

    Using the parameters values given in Table 3, we perform numerical simulations with various values of $\varepsilon$. The results are given in Figure 5.

    Figure 5. Dynamics for different values of $\varepsilon$. On the left intracellular; the lactate trajectories seem not to differ a lot. On the right, the value of $\varepsilon$ is related to the dip stiffness for the capillary lactate trajectories.

    While the intracellular lactate trajectories seem not to differ a lot, the capillary lactate trajectories show different initial dynamics. The smaller $\varepsilon$ is, the steeper the dip is up to $\varepsilon = 0$, where there is no dip.

    Remark 7. An approach based on singular perturbation theory has been made on this model by Lahutte-Auboin et al. [7,8]. There, the authors give a geometrical explanation for the initial lactate dip and prove the existence of a periodic solution of the fast-slow system under a repetitive sequence of identical stimuli. In addition, our approach gives an estimate on the rate of convergence with respect to the parameters, which is usually not the case with singular perturbation theory.

    Using the parameters given in Table 3, we now test different values for $J$. The results are given in Figure 6.

    Figure 6. Dynamics for different values for $J$. On the right, the intracellular lactate trajectories are divided into two groups : for $J \in \{1, 0.1, 0.01 \}$, the concentration seems to explode, while for $J \in \{0.001, 0.0001\}$, it seems more stable. On the right the capillary lactate trajectories are devided into these two groups. For the first one, we can see a dip, while, for the second one, the steady state is not quickly reached.

    There is a limit value of $J$, denoted by $J_{lim}$, such that there is an equilibrium only for $J <J_{lim}$. With these parameters values, we have :

    $J_{lim} = 0.00851 \text{ mM.s$^{-1}$}.$

    There are two types of dynamics : those with $J <J_{lim}$ for which there is a steady state and those with $J>J_{lim}$ for which the intracellular lactate trajectory explodes.

    Experimental data. In this section we compare typical results obtained by using the model (with constant $J$ and $F$) with in vivo data. This model is known to give good results when fitted to experimental data in small time variations (seconds) [2]. We want here to test its robustness on larger time variations (days).

    For each five patients we have four lactate concentration measures (only three for patient 1) separated from each other by more than $80$ days. Biological data were collected from patients exhibiting low grade gliomas (WHO grade 2) histologically proven, using monovoxel proton MR spectroscopy sequences performed on a same whole body 3 Tesla magnet (Verio, Siemens Ag) using specific 32 channels head coil. Raw data have been performed under the JMRUI software for appropriate quantification of metabolites, especially lactate concentration.

    We are unable to distinguish between capillary lactate and intracellular lactate using imaging data. Therefore lactate concentration measures are the sum of the capillary lactate and intracellular lactate concentrations.

    Because lactate concentrations variations are intrinsic and depend on lactate exchanges, we assume that it is relevant to adjust the initial values ($\bar{u}_0$ and $\bar{v}_0$) and the exchanges with neighboring cells ($J$) only. We give the other parameters values in Table 4.

    Table 4. Parameters values.
    ParameterValueUnit
    $T$0.1mM.d$^{-1}$
    $k$3.5mM
    $k'$3.5mM
    $L$0.3mM
    $F$0.0272d$^{-1}$
    $\varepsilon$0.1d$^{-1}$
     | Show Table
    DownLoad: CSV

    The results are given in Figure 7. Fitted values of $\bar{u}_0$, $\bar{v}_0$ and $J$ for each patient are given in Table 5.

    Figure 7. Lactate concentration changes in a local brain part. Lactate concentration is given in mM (vertical axis) and time in days (horizontal axis). The red dots stand for medical data values, while the model simulations are displayed in continuous lines. While the four first patients exhibit Grompertz growth of their brain lactate concentration, patient 5 lactate concentration decreases in time. All the dynamics simulations tend to the steady state given in section 2.
    Table 5. Fitted values of $\bar{u}_0$, $\bar{v}_0$ and $J$.
    Patient $\bar{u}_0$ (mM) $\bar{v}_0$ (mM) $J$ (mM.d$^{-1}$)
    $1$ $0.025$ $0.329$ $0.026$
    $2$ $0.017$ $0.320$ $0.010$
    $3$ $0.034$ $0.338$ $0.001$
    $4$ $0.146$ $0.460$ $0.036$
    $5$ $1.817$ $2.291$ $0.007$
     | Show Table
    DownLoad: CSV

    Our model (with constant $J$ and $F$) is consistent with biological data. it is able to predict what happens after a lactate spike, when the brain sets up a huge regulation to turn back to an acceptable lactate concentration.


    6. Discussion

    In this study we analyze a model for lactate kinetics first given in [2]. This model is a first step in view of a better understanding of lactate dynamics in the brain. Lactate has a key role in neuroenergetics. Therefore studying its dynamics in the brain is necessary to better understand the energetic breakdown which is observed, for example in tumors. This model is known to give good results when fitted with experimental data [2], [8]. However, to the best of our knowledge, no mathematical analysis has been made to show the existence and uniqueness of the solution and conditions for bounds on the solution, but also comparisons between the original and limit systems.

    In this paper, we study the original and limit systems and obtain existence, uniqueness and bounds on the solutions for the two systems. We also give a condition on $J$ which ensures the existence of a locally stable steady state. Moreover, we give an upper estimate on the difference between the solutions of the two systems. We also give several numerical simulations, for different values of $\varepsilon$ and $J$. Finally we confront the model with in vivo data.

    When confronted with imaging data from NMR spectroscopy and perfusion, the model provides good results. Because there are large time variations, we cannot ensure that all the parameters remain constant in time. Therefore constant parameters are not good for explaining hard changes on the lactate concentration dynamics such as shifting from a decreasing concentration to an increasing one. Despite this, they can explain what happens after a lactate spike.

    Differences in lactate dynamics suggest that there are several glioma profiles with different typical kinetics. This could indicate that non-agressive low grade gliomas show an increasing lactate concentration and then move to more agressive form (WHO Ⅱ+ to WHO Ⅲ+). At this stage the glioma will exhibit angiogenesis, modified proteins and altered transporters, which leads to fluctuating lactate kinetics [6]. This point should be considered as a critical one because of its therapeutical management consequences. Yet the patient should be referred to more agressive therapeutics such as radiotherapy or chemotherapy. Also the imaging control frequency should be restrained as well.

    As already mentioned in [10], an initial dip exists in the brain lactate dynamics. This dip could be mathematically explained by the different initial values of the capillary lactate concentration between the original and limit systems. Therefore the dip can be biologically explained by compartment volume modifications.

    It cannot be excluded that $J$ stands only because the model is build to explain a local brain part dynamics. Then lactate exchanges between cells and the extracellular space have to be better studied to find a biologically relevant function $J$ or other models with a different way to take these interactions into account. Despite this, the function $J$ is described here with minimal assumptions. Therefore, this allows us to use this analysis with further choices for $J$ or modified systems.

    Indeed one perspective is to build more complex and suitable models for brain metabolism. Adding oxygen and glucose dynamics to this model can be the next step in view of a more accurate description of energy dynamics in the brain. It could also be interesting to build a model with different cell types (such as astrocyte and neuron), for a better understanding of the brain fuel substrate fluxes.


    Acknowledgments

    The authors wish to thank an anonymous referee for her/his careful reading of the paper and helpful comments.


    [1] Oren A (2015) Halophilic microbial communities and their environments. Curr Opin Biotechnol 33: 119–124. doi: 10.1016/j.copbio.2015.02.005
    [2] Oren A (2014) Taxonomy of halophilic Archaea: current status and future challenges. Extremophiles 18: 825–834. doi: 10.1007/s00792-014-0654-9
    [3] Gunde-Cimerman N, Ramos J, Plemenitas A (2009) Halotolerant and halophilic fungi. Mycol Res 113: 1231–1241. doi: 10.1016/j.mycres.2009.09.002
    [4] Hosseini TA, Shariati M (2009) Dunaliella Biotechnology: methods and applications. J Appl Microbiol 107: 14–35. doi: 10.1111/j.1365-2672.2009.04153.x
    [5] Ventosa A, Nieto JJ, Oren A (1998) Biology of moderately halophilic aerobic bacteria. Microbiol Mol Biol Rev 62: 504–544.
    [6] Waditee R, Bhuiyan MN, Rai V, et al. (2005) Genes for direct methylation of glycine provide high levels of glycinebetaine and abiotic-stress tolerance in Synechococcus and Arabidopsis. Proc Natl Acad Sci USA 102: 1318–1323. doi: 10.1073/pnas.0409017102
    [7] DasSarma S, DasSarma P (2015) Halophiles and their enzymes: negativity put to good use. CurrOpinMicrobiol 25: 120–126.
    [8] Arakawa T, Tokunaga M (2005) Electrostatic and hydrophobic interactions play a major role in the stability and refolding of halophilic proteins. Protein Pept Lett 11: 125–132.
    [9] DasSarma S, Berquist BR, Coker JA, et al. (2006) Post-genomics of the model haloarchaeon Halobacterium sp. NRC-1. Saline Systems. 2:3. doi: 10.1186/1746-1448-2-3
    [10] Hutcheon GW, Vasisht N, Bolhuis A (2005) Characterization of a highly stable alpha-amylase from the halophilic archaeon Haloarcula hispanica. Extremophiles 9: 487–495. doi: 10.1007/s00792-005-0471-2
    [11] Fukushima T, Mizuki T, Echigo A, et al. (2005) Organic solvent tolerance of halophilic alpha-amylase from a Haloarchaeon, Haloarcula sp. strain S-1. Extremophiles 9: 85–89. doi: 10.1007/s00792-004-0423-2
    [12] Waditee-Sirisattha R, Kageyama H, Sopun W, et al. (2014) Identification and upregulation of biosynthetic genes required for accumulation of Mycosporine-2-glycine under salt stress conditions in the halotolerant cyanobacterium Aphanothece halophytica. Appl Environ Microbiol 80: 1763–1769. doi: 10.1128/AEM.03729-13
    [13] Chen D, Feng J, Huang L, et al. (2014) Identification and characterization of a new erythromycin biosynthetic gene cluster in Actinopolyspora erythraea YIM90600, a novel erythronolide-producing halophilic actinomycete isolated from salt field. PLoS One 9:e108129. doi: 10.1371/journal.pone.0108129
    [14] Falb M, Müller K, Königsmaier L, et al. (2008) Metabolism of halophilic archaea. Extremophiles 12: 177–196. doi: 10.1007/s00792-008-0138-x
    [15] Oren A (2013) Salinibacter: an extremely halophilic bacterium with archaeal properties. FEMS Microbiol Lett 342: 1–9. doi: 10.1111/1574-6968.12094
    [16] Gammone MA, Riccioni G, D'Orazio N (2015) Marine carotenoids against oxidative stress: Effects on human health. Mar Drugs 13: 6226–6246. doi: 10.3390/md13106226
    [17] Alvarado C, Alvarez P, Jiménez L, et al. (2005) Improvement of leukocyte functions in young prematurely aging mice after a 5-week ingestion of a diet supplemented with biscuits enriched in antioxidants. Antioxid Redox Signal 7: 1203–1210. doi: 10.1089/ars.2005.7.1203
    [18] Jehlička J, Edwards HG, Oren A (2013) Bacterioruberin and salinixanthin carotenoids of extremely halophilic Archaea and Bacteria: a Raman spectroscopic study. Spectrochim Acta A Mol Biomol Spectrosc 106: 99–103. doi: 10.1016/j.saa.2012.12.081
    [19] Walter MH, Strack D (2011) Carotenoids and their cleavage products: biosynthesis and functions. Nat Prod Rep 28: 663–692. doi: 10.1039/c0np00036a
    [20] Christaki E, Bonos E, Giannenas I, et al. (2013) Functional properties of carotenoids originating from algae. J Sci Food Agric 93: 5–11. doi: 10.1002/jsfa.5902
    [21] Ohyanagi N, Ishido M, Suzuki F, et al. (2009) Retinoid ameliorates experimental autoimmune myositis, with modulation of the cell differentiation and antibody production in vivo. Arthritis Rheum 60: 3118–3127. doi: 10.1002/art.24930
    [22] Vachali P, Bhosale P, Bernstein PS (2012) Microbial carotenoids. Methods Mol Biol 898: 41–59. doi: 10.1007/978-1-61779-918-1_2
    [23] Shumskaya M, Wurtzel ET (2013) The carotenoid biosynthetic pathway: thinking in all dimensions. Plant Sci 208: 58–63. doi: 10.1016/j.plantsci.2013.03.012
    [24] Massyuk NP (1966) Mass culture of the carotene containing alga Dunaliella salina. Teod Ukr Bot Zh 23: 12–19.
    [25] Borowitzka MA (1999) Commercial production of microalgae: ponds, tanks, tubes and fermenters. J Biotechnol 70:313–321. doi: 10.1016/S0168-1656(99)00083-8
    [26] Hejazi MA, Holwerda E, Wijffels RH (2004) Milking microalga Dunaliella salina for -carotene production in two-phase bioreactors. Biotechnol Bioeng 85:475–481. doi: 10.1002/bit.10914
    [27] Wichuk K, Brynjólfsson S, Fu W (2014) Biotechnological production of value-added carotenoids from microalgae: Emerging technology and prospects. Bioengineered 5:204–208. doi: 10.4161/bioe.28720
    [28] Papaioannou EH, Kyriakides ML, Karabelas AJ (2015) Natural origin lycopene and its 'green' downstream processing. Crit Rev Food Sci Nutr. DOI:10.1080/10408398.2013.817381.
    [29] Hong ME, Choi YY, Sim SJ (2016) Effect of red cyst cell inoculation and iron (II) supplementation on autotrophic astaxanthin production by Haematococcus pluvialis under outdoor summer conditions. J Biotechnol 218: 25–33. doi: 10.1016/j.jbiotec.2015.11.019
    [30] Gao Q, Garcia-Pichel F (2011) Microbial ultraviolet sunscreens. Nat Rev Microbiol 9: 791-802. doi: 10.1038/nrmicro2649
    [31] Shick JM and Dunlap WC (2002) Mycosporine-like amino acids and related gadusols: biosynthesis, accumulation, and UV-protective functions in aquatic organisms. Annu Rev Physiol 64:223–262. doi: 10.1146/annurev.physiol.64.081501.155802
    [32] Carreto JI, Carignan MO (2011) Mycosporine-like amino acids: relevant secondary metabolites. Chemical and ecological aspects. Mar Drugs 9: 387–446.
    [33] Dunlap WC, Shick JM (1998) Ultraviolet radiation-absorbing mycosporine-like amino acids in coral reef organisms: a biochemical and environmental perspective. J Phycol 34: 418–430. doi: 10.1046/j.1529-8817.1998.340418.x
    [34] Nazifi E, Wada N, Yamaba M, et al. (2013) Glycosylated porphyra-334 and palythine-threonine from the terrestrial cyanobacterium Nostoc commune. Mar Drugs 11: 3124–3154. doi: 10.3390/md11093124
    [35] Matsui K, Nazifi E, Kunita S, et al. (2011) Novel glycosylated mycosporine-like amino acids with radical scavenging activity from the cyanobacterium Nostoc commune. J Photochem Photobiol B 105: 81–89. doi: 10.1016/j.jphotobiol.2011.07.003
    [36] Rastogi RP, Sinha RP, Moh SH, et al. (2014) Ultraviolet radiation and cyanobacteria. J Photochem Photobiol B 141: 154–169. doi: 10.1016/j.jphotobiol.2014.09.020
    [37] Llewellyn CA, White DA, Martinez-Vincente V, et al. (2012) Distribution of mycosporine-like amino acids along a surface water meridional transect of the Atlantic. Microb Ecol 64: 320–333. doi: 10.1007/s00248-012-0038-6
    [38] Rastogi RP, Richa, Sinha RP, et al. (2010) Photoprotective compounds from marine organisms. J Ind Microbiol Biotechnol 37: 537–358. doi: 10.1007/s10295-010-0718-5
    [39] Carreto JI, Carignan MO (2011) Mycosporine-like amino acids: relevant secondary metabolites. Chemical and ecological aspects. (2011) Mar Drugs 9: 387–446.
    [40] Volkmann M, Gorbushina AA, Kedar L, et al. (2006) Structure of euhalothece-362, a novel red-shifted mycosporine-like amino acid, from a halophiliccyanobacterium (Euhalothece sp.). FEMS Microbiol Lett 258: 50–54. doi: 10.1111/j.1574-6968.2006.00203.x
    [41] Oren A (1997) Mycosporine-like amino acids as osmotic solutes in a community of halophilic cyanobacteria. Geomicrobiol J 14:231–240. doi: 10.1080/01490459709378046
    [42] Ryu J, Park SJ, Kim IH, et al. (2014) Protective effect of porphyra-334 on UVA-induced photoaging in human skin fibroblasts. Int J Mol Med 34: 796–803.
    [43] Suh SS, Hwang J, Park M, et al. (2014) Anti-inflammation activities of mycosporine-like amino acids (MAAs) in response to UV radiation suggest potential anti-skin aging activity. Mar Drugs 12: 5174–5187. doi: 10.3390/md12105174
    [44] Torres A, Enk CD, Hochberg M, et al. (2006) Porphyra-334, a potential natural source for UVA protective sunscreens. PhotochemPhotobiolSci 5: 432–435.
    [45] Masaki K, Dunlap WC, Yamamoto Y, et al. (1996) Toyo Suisan Kaisha Pty. Ltd, Japanese Patent Application 9604230.
    [46] Dunlap WC, Shick JM (1998) Ultraviolet radiation-absorbing mycosporine-like amino acids in coral reef organisms: a biochemical and environment perspective. J Phycol 34: 418–430. doi: 10.1046/j.1529-8817.1998.340418.x
    [47] Hershkovitz N, Oren A, Cohen Y (1991) Accumulation of trehalose and sucrose in cyanobacteria exposed to matric water stress. Appl Environ Microbiol 57: 645–648.
    [48] Bolen DW, Baskakov IV (2001) Theosmophobic effect: natural selection of a thermodynamic force in protein folding. J Mol Biol 310:955–963. doi: 10.1006/jmbi.2001.4819
    [49] Hagemann M, Pade, N (2015) Heterosides - compatible solutes occurring in prokaryotic and eukaryotic phototrophs. Plant Biol 17: 927–934. doi: 10.1111/plb.12350
    [50] Rhodes D, Hanson AD (1993) Quaternary ammonium and tertiary sulfonium compounds in higher plants. Annu Rev Plant Physiol Plant Mol Biol 44: 357–384. doi: 10.1146/annurev.pp.44.060193.002041
    [51] Klahn S, Hagemann M (2011) Compatible solute biosynthesis in cyanobacteria. Environ Microbiol 13: 551–562. doi: 10.1111/j.1462-2920.2010.02366.x
    [52] Higo A, Katoh H, Ohmori K, et al. (2006) The role of a gene cluster for trehalose metabolism in dehydration tolerance of the filamentous cyanobacterium Anabaena sp. PCC 7120. Microbiology 152: 979–987.
    [53] Kolman MA, Nishi CN, Perez-Cenci M, et al. (2015) Sucrose in cyanobacteria: from a salt-response molecule to play a key role in nitrogen fixation. Life (Basel) 5: 102–126.
    [54] Hagemann M, Richter S, Mikkat S (1997) TheggtA gene encodes a subunit of the transport system for the osmoprotective compound glucosylglycerol in Synechocystis sp. strain PCC 6803. J Bacteriol 179: 714–720.
    [55] Fulda S, Mikkat S, Huang F, et al. (2006) Proteome analysis of salt stress response in the cyanobacterium Synechocystissp. strain PCC 6803. Proteomics 6: 2733–2745.
    [56] Ferjani A, Mustardy L, Sulpice R, et al. (2003) Glucosylglycerol, a compatible solute, sustains cell division under salt stress. Plant Physiol 131: 1628–1637. doi: 10.1104/pp.102.017277
    [57] Klahn S, Hagemann M (2011) Compatible solute biosynthesis in cyanobacteria. Environ Microbiol 13: 551–562. doi: 10.1111/j.1462-2920.2010.02366.x
    [58] Goh F, Barrow KD, Burns BP, et al. (2010) Identification and regulation of novel compatible solutes from hypersalinestromatolite-associated cyanobacteria. Arch Microbiol 192: 1031–1038. doi: 10.1007/s00203-010-0634-0
    [59] Roberts MF, Lai MC, Gunsalus RP (1992) Biosynthetic pathways of the osmolytes N epsilon-acetyl-beta-lysine, beta-glutamine, and betaine in Methanohalophilus strain FDF1 suggested by nuclear magnetic resonance analyses. J Bacteriol 174:6688–6693.
    [60] Laloknam S, Tanaka K, Buaboocha T, et al. (2006) Halotolerant cyanobacterium Aphanothece halophytica contains a betaine transporter active at alkaline pH and high salinity. Appl Environ Microbiol 72:6018–6026. doi: 10.1128/AEM.00733-06
    [61] Lentzen G, Schwarz T (2006) Extremolytes: natural compounds from extremophiles for versatile applications. Appl Microbiol Biotechnol 72: 623–634. doi: 10.1007/s00253-006-0553-9
    [62] Graf R, Anzali S, Buenger J, et al. (2008) The multifunctional role of ectoine as a natural cell protectant. Clin Dermatol 26: 326–333. doi: 10.1016/j.clindermatol.2008.01.002
    [63] Beyer N, Driller H, Bünger J (2000) Ectoine - a innovative, multi-functional active substance for the cosmetic industry. Seifen ÖleFette Wachse J 126: 26–29.
    [64] Barth S, Huhn M, Matthey B, et al. (2000) Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl Environ Microbiol 66: 1572–1579. doi: 10.1128/AEM.66.4.1572-1579.2000
    [65] Kunte, HJ, Lentzen, G, Galinski, EA (2014) Industrial production of the cell protectant ectoine: protection mechanisms, processes, and products. Curr >B>iotechnol 3: 10–25.
    [66] Grammann, K, Volke, A, Kunte, HJ (2002) New type of osmoregulated solute transporter identified in halophilic members of the bacteria domain: TRAP transporter TeaABCmediates uptake of ectoine and hydroxyectoine in Halomonas elongata DSM 2581(T). J Bacteriol 184:3078–3085. doi: 10.1128/JB.184.11.3078-3085.2002
    [67] Schwibbert K, Marin-Sanguino A, Bagyan I, et al. (2011) A blueprint of ectoine metabolism from the genome of the industrial producer Halomonas elongata DSM 2581 T. Environ Microbiol 13:1973–1994. doi: 10.1111/j.1462-2920.2010.02336.x
    [68] Jaeger K-E, Eggert T (2002) Lipases for biotechnology. CurrOpinBiotechnol 13: 390–397.
    [69] Pérez-Pomares F, Bautista V, Ferrer J, et al. (2003) Amylase activity from the halophilic archaeon Haloferax mediterranei. Extremophiles 7: 299–306. doi: 10.1007/s00792-003-0327-6
    [70] Pérez-Pomares F, Díaz S, Bautista V, et al. (2009) Identification of several intracellular carbohydrate-degrading activities from the halophilic archaeon Haloferax mediterranei. Extremophiles 13: 633–641. doi: 10.1007/s00792-009-0246-2
    [71] Pérez D, Martín S, Fernández-Lorente G, et al. (2011) A novel halophilic lipase, LipBL, showing high efficiency in the production of eicosapentaenoic acid (EPA). PLoS One 6:e23325. doi: 10.1371/journal.pone.0023325
    [72] Amoozegar MA, Salehghamari E, Khajeh K, et al. (2008) Production of an extracellular thermohalophilic lipase from a moderately halophilic bacterium, Salinivibrio sp. strain SA-2. J Basic Microbiol 48: 160–167. doi: 10.1002/jobm.200700361
    [73] Karbalaei-Heidari HR, Amoozegar MA, Hajighasemi M, et al. (2009) Production, optimization and purification of a novel extracellular protease from the moderately halophilic bacterium Halobacillus karajensis. J Ind Microbio Biotechnol 36: 21–27. doi: 10.1007/s10295-008-0466-y
    [74] Dang H, Zhu H, Wang J, et al. (2009) Extracellular hydrolytic enzyme screening of culturable heterotrophic bacteria from deep-sea sediments of the Southern Okinawa Trough. World J Microbiol Biotechnol 25: 71–79. doi: 10.1007/s11274-008-9865-5
    [75] Moreno ML, Piubeli F, Bonfá MR, et al. (2012) Analysis and characterization of cultivable extremophilic hydrolytic bacterial community in heavy-metal-contaminated soils from the Atacama Desert and their biotechnological potentials. J Appl Microbiol 113: 550–559. doi: 10.1111/j.1365-2672.2012.05366.x
    [76] Hedlund BP, Dodsworth JA, Murugapiran SK, et al. (2014) Impact of single-cell genomics and metagenomics on the emerging view of extremophile "microbial dark matter". Extremophiles 18: 865–875. doi: 10.1007/s00792-014-0664-7
    [77] López-Pérez M, Ghai R, Leon MJ, et al. (2013) Genomes of "Spiribacter", a streamlined, successful halophilic bacterium. BMC Genomics 14: 787. doi: 10.1186/1471-2164-14-787
    [78] Yakovleva I, Bhagooli R, Takemura A, et al. (2004) Differential susceptibility to oxidative stress of two scleractinian corals: antioxidant functioning of mycosporine-glycine. CompBiochem Physiol B 139:721–730. doi: 10.1016/j.cbpc.2004.08.016
    [79] Helbling EW, Chalker BE, Dunlap WC, et al. (1996) Photoacclimation of Antarctic marine diatoms to solar ultraviolet radiation. J Exp Mar Biol Ecol 204:85–101. doi: 10.1016/0022-0981(96)02591-9
    [80] Vale P (2015) Effects of light and salinity stresses in production of mycosporine-like amino acids by Gymnodinium catenatum(dinophyceae). Photochem Photobiol 91:1112–1122. doi: 10.1111/php.12488
  • This article has been cited by:

    1. A. Perrillat-Mercerot, C. Guillevin, A. Miranville, R. Guillevin, Using mathematics in MRI data management for glioma assesment, 2019, 01509861, 10.1016/j.neurad.2019.11.004
    2. Angélique Perrillat-Mercerot, Alain Miranville, Abramo Agosti, Elisabetta Rocca, Pasquale Ciarletta, Rémy Guillevin, Partial differential model of lactate neuro-energetics: analytic results and numerical simulations, 2021, 1477-8599, 10.1093/imammb/dqaa016
    3. Angélique Perrillat-Mercerot, Nicolas Bourmeyster, Carole Guillevin, Alain Miranville, Rémy Guillevin, Mathematical Modeling of Substrates Fluxes and Tumor Growth in the Brain, 2019, 67, 0001-5342, 149, 10.1007/s10441-019-09343-1
    4. Remy Guillevin, 2018, Chapter 5, 978-3-319-78924-8, 93, 10.1007/978-3-319-78926-2_5
    5. Lu Li, Alain Miranville, Rémy Guillevin, Cahn–Hilliard Models for Glial Cells, 2020, 0095-4616, 10.1007/s00245-020-09696-x
    6. Monica Conti, Stefania Gatti, Alain Miranville, Mathematical analysis of a model for proliferative-to-invasive transition of hypoxic glioma cells, 2019, 189, 0362546X, 111572, 10.1016/j.na.2019.111572
    7. Laurence Cherfils, Stefania Gatti, Alain Miranville, Rémy Guillevin, Analysis of a model for tumor growth and lactate exchanges in a glioma, 2020, 0, 1937-1179, 0, 10.3934/dcdss.2020457
    8. Hussein Raad, Laurence Cherfils, Cyrille Allery, Rémy Guillevin, Optimal control of a model for brain lactate kinetics, 2023, 18758576, 1, 10.3233/ASY-221823
    9. Laurence Cherfils, Stefania Gatti, Carole Guillevin, Alain Miranville, Rémy Guillevin, On a tumor growth model with brain lactate kinetics, 2022, 39, 1477-8599, 382, 10.1093/imammb/dqac010
    10. Hawraa Alsayed, Hussein Fakih, Alain Miranville, Ali Wehbe, On an Optimal Control Problem Describing Lactate Transport Inhibition, 2023, 0022-3239, 10.1007/s10957-023-02271-8
    11. Hussein Raad, Cyrille Allery, Laurence Cherfils, Carole Guillevin, Alain Miranville, Thomas Sookiew, Luc Pellerin, Rémy Guillevin, Simulation of tumor density evolution upon chemotherapy alone or combined with a treatment to reduce lactate levels, 2024, 9, 2473-6988, 5250, 10.3934/math.2024254
    12. Nour Ali, Hussein Fakih, Ali Wehbe, On a singular mathematical model for brain lactate kinetics, 2024, 0170-4214, 10.1002/mma.9898
    13. Laurence Cherfils, Stefania Gatti, Alain Miranville, Hussein Raad, Rémy Guillevin, Optimal control of therapies on a tumor growth model with brain lactate kinetics, 2024, 0, 1937-1632, 0, 10.3934/dcdss.2024032
    14. Giulia Cavalleri, Pierluigi Colli, Alain Miranville, Elisabetta Rocca, On a brain tumor growth model with lactate metabolism, viscoelastic effects, and tissue damage, 2026, 87, 14681218, 104419, 10.1016/j.nonrwa.2025.104419
    15. Grazia Policastro, Vincenzo Luongo, Luigi Frunzo, Nick Cogan, Massimiliano Fabbricino, A mechanistic mathematical model for photo fermentative hydrogen and polyhydroxybutyrate production, 2023, 20, 1551-0018, 7407, 10.3934/mbe.2023321
  • Reader Comments
  • © 2016 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(12026) PDF downloads(2246) Cited by(61)

Article outline

Figures and Tables

Tables(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog